Kenvue India presents report on ‘The Hydration Gap for Non-Diarrheal Illnesses’
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
Aims to become India’s leading cancer testing company
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
Emcure Pharmaceuticals has reported total income of Rs. 2,037.63 crores during the period ended September 30, 2024
Subscribe To Our Newsletter & Stay Updated